Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated ...
On June 18, 2016, the Federal Department of Health published a Notice of Intent to amend the Food and Drug Regulations and the Medical Devices Regulations to implement key authorities under Vanessa's Law...
On January 21, 2016, various hospitals, natural health product manufacturers,
physicians and pharmaceutical companies found themselves specifically named by
Health Canada in a published list of health product advertising complaints ...
The Canadian Intellectual Property Office has issued a revised guidance which provides clear instructions on how to approach medical use claims and determine whether such claims are eligible for patent protection.
The proposed European regulatory regime will merge the directives on Medical Devices and Active Implantable Medical Devices into a single regulation and wholly replace the current regulation on In Vitro Diagnostic Medical Devices.
An overview of how and where regulatory controls apply to medical devices in India. Plus: key judgements passed by the Hon’ble Supreme Court; changes in corporate and commercial
matters; and case laws in indirect taxation.
China is encouraging foreign investment into the pharmaceutical distribution industry by lifting previously entrenched barriers in ‘restricted’ categories in the field. Given that the government is additionally taking steps to reduce drug prices down the distribution chain, foreign manufacturers are electing to cut out the middleman and establish their own distribution business with a view to maxing out on profits. Jack Wang and Ma Ya of Freshfields Bruckhaus Deringer take us through the government’s efforts to boost foreign investment and consolidate the drug distribution industry in the PRC.
Offering huge potential for expansion and returns, almost every active economy in Asia is making efforts to actively develop a niche in the life sciences industry. In ‘Asia’s winning formula’ Asian-Counsel discusses how countries are positioning themselves to carve out niches in this area of living jurisprudence. The report also features expert articles focussing on particular developments in China, Japan, India and Singapore.